Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services. We show 37 historical shares outstanding datapoints in our CTLT shares outstanding history coverage, used to compute CTLT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CTLT market cap history over the course of time is important for investors
interested in comparing CTLT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CTLT versus a peer is one thing; comparing
CTLT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CTLT can fluctuate over the course of history.
With this page we aim to empower investors researching CTLT by allowing them to research the CTLT market cap history. |
Free CTLT Email Alerts:
Video: The Importance of Market Cap
